Computational Exploration of a Diverse Flavonoid Library for Targeted Allosteric Inhibition of AKT1 in Cancer Therapy

Mohd Rehan1,2, Ishfaq A Sheikh3,2, Mohd Suhail3,2

  • 1King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia mrtahir@kau.edu.sa mrehan786@gmail.com.

Anticancer Research
|January 31, 2025
PubMed
Abstract

Insights

This study computationally identified 10 flavonoids as potential allosteric inhibitors of AKT1 (AKT serine/threonine kinase 1), a key target in cancer. The top compound showed strong binding and stability, paving the way for new cancer therapies.

Area of Science:

  • Computational chemistry
  • Drug discovery
  • Oncology

Background:

  • AKT serine/threonine kinase 1 (AKT1) is crucial for cancer cell survival and proliferation.
  • AKT1 is a validated therapeutic target for cancer treatment.
  • Identifying novel allosteric inhibitors is essential for effective cancer therapy.

Purpose of the Study:

  • To computationally screen a flavonoid library for novel allosteric AKT1 inhibitors.
  • To identify compounds with favorable binding interactions and stable binding poses within the AKT1 allosteric site.

Main Methods:

  • Computational screening of a large flavonoid library against AKT1.
  • Molecular docking to predict binding affinities and interactions.
  • Molecular dynamics simulations to assess the stability of top-ranked compounds.

Main Results:

  • Ten flavonoids were identified as potential allosteric AKT1 inhibitors.
  • Key residues (Trp-80, Ile-84, Tyr-272, Arg-273, Asp-292) were critical for binding.
  • The top flavonoid (CID 108790283) exhibited strong binding affinity (-10.64 kcal/mol) and stable interactions.
  • Molecular dynamics confirmed the stability of the lead compound in the allosteric site.

Conclusions:

  • This study computationally identified promising flavonoid-based allosteric AKT1 inhibitors.
  • The findings support further experimental validation for potential cancer therapeutics.
  • The identified compounds offer a new avenue for developing targeted cancer treatments.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K